Patents Assigned to Hadasit Medical Research Services and Development Ltd.
  • Publication number: 20190209274
    Abstract: A system and method of automated formation of a preparation stub, based on an a priori created computational geometrical model, configured to conform to a prefabricated fixed dental prosthesis, is described. The system includes a digital imaging facility with an image acquiring device and a three-dimensional data digitizer, a modeling facility with an exterior surface design module and an interior surface design module, a fabrication facility operatively with a computer-aided manufacturing module, as well as an application facility including an ablation tool and in-situ preparation module; application facility preferably includes an intra-oral feedbacking appliance with a distance measurement probe for automated feedback-controlled formation of a preparation stub.
    Type: Application
    Filed: December 12, 2018
    Publication date: July 11, 2019
    Applicants: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD, ROBOTOO INNOVATION LTD
    Inventors: Uri BARAK, Eyal TARAZI
  • Patent number: 10344073
    Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: July 9, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Abraham Rutenberg, Ronny Uzana, Michal Lotem, Arthur Machlenkin, Galit Eisenberg, Tamar Peretz-Yablonsky, Shoshana Frankenburg, Roni Engelstein
  • Patent number: 10328098
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Grant
    Filed: July 10, 2016
    Date of Patent: June 25, 2019
    Assignees: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Ya'acov, Smadar Cohen, Tsiona Elkayam
  • Patent number: 10314873
    Abstract: A method for treating a disease comprising administering to a mammal in need thereof an effective dosage of an extract of a plant of the genus Hoodia, wherein the disease is selected from the group consisting of immune-mediated disorders, immune-associated disorders, inflammatory diseases, coronary disease, insulin resistance and liver-related diseases. In a preferred embodiment, the Hoodia is Hoodia parviflora. Also disclosed is a pharmaceutical composition for treating the above diseases comprising an effective dosage of an extract of a plant of the genus Hoodia.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: June 11, 2019
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, DESERT LABS AGRICULTURE COOPERATIVE ASSOCIATION LTD.
    Inventors: Refael Aharon, Yaron Ilan
  • Publication number: 20190167179
    Abstract: A method of neuropsychological analysis comprises: presenting to a subject, by a user interface, a subject-specific cognitive task having at least one task portion selected from the group consisting of a time-domain task portion, a space-domain task portion, and a person-domain task portion. The method also comprises receiving responses entered by the subject using the user interface for each of the task portions, representing the responses as a set of parameters, and classifying the subject into one of a plurality of cognitive function classification groups, based on the set of parameters.
    Type: Application
    Filed: August 7, 2017
    Publication date: June 6, 2019
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventor: Shahar ARZY
  • Patent number: 10307462
    Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: June 4, 2019
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick
  • Publication number: 20190070111
    Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
    Type: Application
    Filed: November 8, 2018
    Publication date: March 7, 2019
    Applicants: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Ruth GABIZON, Haim OVADIA, Oded ABRAMSKY, Shlomo MAGDASSI, Liraz LARUSH
  • Publication number: 20190053487
    Abstract: The present invention relates to anti-microbially active micro and nanoparticles, compositions comprising same, and use thereof for inhibiting bacterial growth and biofilm formation on surfaces or devices, e.g., dental surfaces or devices. The present invention further discloses methods of making such anti-microbially active micro or nanoparticles.
    Type: Application
    Filed: February 26, 2017
    Publication date: February 21, 2019
    Applicants: NOBIO LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Nathan ZALTSMAN, Ervin I. WEISS
  • Patent number: 10188741
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 29, 2019
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • Publication number: 20190015355
    Abstract: The current invention is a method of preventing and treating certain diseases by preventing the synthesis and/or breakdown of glycogen by the administration of an agent, guaiacol. Diseases that can be prevented and treated by the administration of guaiacol include but are not limited to glycogen storage disease type IV (GSD-IV), adult polyglucosan body disease (APBD), and Lafora disease (LD). The invention also includes methods and tools for screening for agents that prevent and treat these diseases as well as basic research, specifically in the form of cells and cell lines that produce detectable polyglucosan.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 17, 2019
    Applicants: The Trustees of Couumbia University in the City of New York, Hadasit Medical Research Services and Development Ltd.
    Inventors: Hasan Orhan AKMAN, Salvatore DIMAURO, Or KAKHLON
  • Publication number: 20190000854
    Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering from type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
    Type: Application
    Filed: May 2, 2018
    Publication date: January 3, 2019
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron ILAN, Doina Cosma ROMAN, Michael HAYDEN, Einat AMIT-ROMACH
  • Patent number: 10166202
    Abstract: The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: January 1, 2019
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services & Development Ltd., Aristotle University of Thessaloniki
    Inventors: Elliot Berry, Yosefa Avraham, Raphael Mechoulam, Yaron Ilan, Yossi Dagon, Iddo Magen, Nicholas Grigoriadis, Theofilos Poutachidis
  • Patent number: 10154961
    Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: December 18, 2018
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Ruth Gabizon, Haim Ovadia, Oded Abramsky, Shlomo Magdassi, Liraz Larush
  • Publication number: 20180343882
    Abstract: Provided are microvesicles isolated from milk, compositions thereof and uses for the preparation of milk formulas. Further provided are microvesicles, including exosomes and/or fat globules which encapsulate various miRNA molecules and uses thereof, as exemplified by supplementing milk formulas.
    Type: Application
    Filed: November 29, 2016
    Publication date: December 6, 2018
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Shimon REIF, Regina GOLAN
  • Publication number: 20180333439
    Abstract: The present invention provides attenuated or inactivated pathogenic bacteria having anti-cancer properties, compositions comprising the bacteria, and use thereof for treating cancers of the urogenital system.
    Type: Application
    Filed: November 10, 2015
    Publication date: November 22, 2018
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Ofer MANDELBOIM, Gilad Benjamin BACHRACH, Chamutal GUR, Vladimir YUTKIN
  • Publication number: 20180312805
    Abstract: A method of generating retinal pigment epithelium cells is disclosed. Cell populations comprising same and uses thereof are also disclosed.
    Type: Application
    Filed: October 26, 2016
    Publication date: November 1, 2018
    Applicants: CELL CURE NEUROSCIENCES LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Benjamin Eithan REUBINOFF, Orna SINGER, Osnat BOHANA-KASHTAN, Ofer WISER
  • Patent number: 10111884
    Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisinin derivatives having anti-viral activity.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: October 30, 2018
    Assignees: Hadasit Medical Research Services and Development Ltd., The Hong Kong University of Science and Technology
    Inventors: Richard K. Haynes, Dana G. Wolf
  • Patent number: 10087232
    Abstract: A method of treating a TNF Alpha associated medical condition selected from the group consisting of obesity, metabolic syndrome, diabetes and a liver disease or disorder is provided. The method comprising enterally administering to a subject in need thereof a therapeutically effective amount of plant cells expressing a TNF Alpha polypeptide inhibitor, thereby treating the TNF Alpha associated medical condition.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: October 2, 2018
    Assignees: Protalix Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron Ilan, Yoseph Shaaltiel, Uri Hanania, Tali Kizhner, Tami Ariel, Svetlana Gingis-Velitski
  • Patent number: 10064927
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: September 4, 2018
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Tamar Peretz, Michal Lotem, Arthur Machlenkin, Shoshana Frankenburg, Inna Ben David, Anna Kuznetz, Yael Gelfand, Galit Eisenberg, Merav Darash Yahana
  • Publication number: 20180215709
    Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
    Type: Application
    Filed: March 16, 2015
    Publication date: August 2, 2018
    Applicants: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., INDIAN INSTITUTE OF SCIENCE
    Inventors: Bernard LERER, Mugesh GOVINDASAMY, Tzuri LIFSCHYTZ